Cargando…

Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?

BACKGROUND: The primary goal of radiotherapy (RT) is to induce cellular damage on malignant cells; however, it is becoming increasingly recognized the important role played by the tumor microenvironment (TME) in therapy outcomes. Therapeutic irradiation of tumor lesions provokes profound cellular an...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Zubiaurre, Inigo, Hellevik, Turid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173661/
https://www.ncbi.nlm.nih.gov/pubmed/37170098
http://dx.doi.org/10.1186/s12964-023-01093-5
_version_ 1785039870511546368
author Martinez-Zubiaurre, Inigo
Hellevik, Turid
author_facet Martinez-Zubiaurre, Inigo
Hellevik, Turid
author_sort Martinez-Zubiaurre, Inigo
collection PubMed
description BACKGROUND: The primary goal of radiotherapy (RT) is to induce cellular damage on malignant cells; however, it is becoming increasingly recognized the important role played by the tumor microenvironment (TME) in therapy outcomes. Therapeutic irradiation of tumor lesions provokes profound cellular and biological reconfigurations within the TME that ultimately may influence the fate of the therapy. MAIN CONTENT: Cancer-associated fibroblasts (CAFs) are known to participate in all stages of cancer progression and are increasingly acknowledged to contribute to therapy resistance. Accumulated evidence suggests that, upon radiation, fibroblasts/CAFs avoid cell death but instead enter a permanent senescent state, which in turn may influence the behavior of tumor cells and other components of the TME. Despite the proposed participation of senescent fibroblasts on tumor radioprotection, it is still incompletely understood the impact that RT has on CAFs and the ultimate role that irradiated CAFs have on therapy outcomes. Some of the current controversies may emerge from generalizing observations obtained using normal fibroblasts and CAFs, which are different cell entities that may respond differently to radiation exposure. CONCLUSION: In this review we present current knowledge on the field of CAFs role in radiotherapy; we discuss the potential tumorigenic functions of radiation-induced senescent fibroblasts and CAFs and we make an effort to integrate the knowledge emerging from preclinical experimentation with observations from the clinics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01093-5.
format Online
Article
Text
id pubmed-10173661
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101736612023-05-12 Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists? Martinez-Zubiaurre, Inigo Hellevik, Turid Cell Commun Signal Review BACKGROUND: The primary goal of radiotherapy (RT) is to induce cellular damage on malignant cells; however, it is becoming increasingly recognized the important role played by the tumor microenvironment (TME) in therapy outcomes. Therapeutic irradiation of tumor lesions provokes profound cellular and biological reconfigurations within the TME that ultimately may influence the fate of the therapy. MAIN CONTENT: Cancer-associated fibroblasts (CAFs) are known to participate in all stages of cancer progression and are increasingly acknowledged to contribute to therapy resistance. Accumulated evidence suggests that, upon radiation, fibroblasts/CAFs avoid cell death but instead enter a permanent senescent state, which in turn may influence the behavior of tumor cells and other components of the TME. Despite the proposed participation of senescent fibroblasts on tumor radioprotection, it is still incompletely understood the impact that RT has on CAFs and the ultimate role that irradiated CAFs have on therapy outcomes. Some of the current controversies may emerge from generalizing observations obtained using normal fibroblasts and CAFs, which are different cell entities that may respond differently to radiation exposure. CONCLUSION: In this review we present current knowledge on the field of CAFs role in radiotherapy; we discuss the potential tumorigenic functions of radiation-induced senescent fibroblasts and CAFs and we make an effort to integrate the knowledge emerging from preclinical experimentation with observations from the clinics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01093-5. BioMed Central 2023-05-11 /pmc/articles/PMC10173661/ /pubmed/37170098 http://dx.doi.org/10.1186/s12964-023-01093-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Martinez-Zubiaurre, Inigo
Hellevik, Turid
Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title_full Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title_fullStr Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title_full_unstemmed Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title_short Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
title_sort cancer-associated fibroblasts in radiotherapy: bystanders or protagonists?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173661/
https://www.ncbi.nlm.nih.gov/pubmed/37170098
http://dx.doi.org/10.1186/s12964-023-01093-5
work_keys_str_mv AT martinezzubiaurreinigo cancerassociatedfibroblastsinradiotherapybystandersorprotagonists
AT hellevikturid cancerassociatedfibroblastsinradiotherapybystandersorprotagonists